Viridian Therapeutics, Inc.
NASDAQ:VRDNBiotechnology
Healthcare
$31.44 -0.88%
-$0.15 today
- Market cap
- $3.57B
- Beta
- 0.90
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$3.53
52W Low $13.18High $34.29
Volume 4.02M
Average 2.86M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$276.39M
FY 2025 · Annual
Investing Cash Flow
-$37.56M
FY 2025 · Annual
Financing Cash Flow
$426.74M
FY 2025 · Annual
-6.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (79.41M) | (129.87M) | (237.73M) | (269.95M) | (342.6M) |
| Depreciation & Amortization | 120K | 255K | 522K | 540K | 460K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.47M | 19.77M | 67.17M | 42.15M | 44.3M |
| Change in Working Capital | 1.72M | 15.96M | (9.43M) | 9.6M | 23.03M |
| Accounts Receivables | (451K) | 349K | 0 | 102K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.66M | 11.52M | (12.04M) | (73K) | 6.56M |
| Other Working Capital | 520K | 4.09M | 2.62M | 9.57M | 16.47M |
| Other Non-Cash Items | 8.52M | 54K | (4.71M) | (14.66M) | (1.58M) |
| Operating Cash Flow | (54.58M) | (93.84M) | (184.17M) | (232.32M) | (276.39M) |
| Capital Expenditures | (338K) | (797K) | (898K) | (511K) | (495K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (188.43M) | (223.26M) | (407.88M) | (695.07M) | (579.28M) |
| Sales of Investments | 114.4M | 108.94M | 314.53M | 466.93M | 542.21M |
| Other Investing Activities | 79K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (74.29M) | (115.13M) | (94.25M) | (228.65M) | (37.56M) |
| Debt Repayment | 0 | 5M | 15M | 0 | 28.88M |
| Common Stock Issued | 114.24M | 291.87M | 125.07M | 453.66M | 348.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.93M) | (18.63M) | 9.41M | (20.92M) | 49.54M |
| Financing Cash Flow | 125.28M | 322.24M | 225.67M | 457.74M | 426.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (3.6M) | 113.28M | (52.75M) | (3.23M) | 112.79M |
| Free Cash Flow | (54.92M) | (94.64M) | (185.07M) | (232.83M) | (276.89M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$342.6M
+ D&A$460.0K
+ Stock-Based Comp$44.3M
+ Deferred Tax$0
+ Working Capital$23.0M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$276.4M
- Capex-$495.0K
= Free Cash Flow-$276.9M
Analysis
FY2025 free cash flow is -$276.9M. FCF conversion is 80.8% of net income. Operating cash flow was -$276.4M, with capex of -$495.0K. The largest bridge item is Stock-Based Comp at $44.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 20, 2026 |
Does VRDN generate free cash flow?
Viridian Therapeutics, Inc. (VRDN) generated -$276.89M of free cash flow in fiscal 2025.
How much operating cash flow does VRDN produce?
Operating cash flow was -$276.39M, before capital expenditures of $495,000.00.
Continue the stock analysis
Jump to another research area for this company.